Table 2.
Cancer | Deregulation | Downstream targets | Phenotypic effect | References |
---|---|---|---|---|
Oligodendrogliomas | Inactivating mutations of FUBP1 | NA | [9, 13, 103–106, 110, 159–162] | |
Gliomas (other subtypes) | FUBP1 ↑ | MYC ↑ | G1/S cell cycle transition ↑ | [15] |
Hepatocellular carcinoma | FUBP1 ↑ | MYC ↑ | Proliferation ↓ | [126] |
Stathmin 1/3 ↑ | Migration ↑ | [6] | ||
P21 ↓, P15 ↓, TNF-α ↓, TRAIL ↓, BIK ↓, NOXA ↓, CCND2 ↑ | Proliferation ↑, apoptosis ↓ | [8] | ||
PE2 upregulates FUBP1 | Proliferation ↑, apoptosis ↓ | [163] | ||
P53 ↓, P21 ↓, BCCIP ↓, TCTP ↑ |
Cell sensitivity to irradiation ↓ | [70] | ||
FIR upregulates FUBP1 | [7] | |||
P21 ↓, BIK ↓, CCND2 ↑, TCTP ↑ | [11] | |||
PI3K/AKT/mTOR upregulate FUBP1 | [164] | |||
Gastric cancer | FUBP1 ↑ | NA | [35, 165] | |
FUBP1 ↑ | MYC ↑ | Tumor growth ↑ | [34] | |
Colorectal carcinoma | FIR ↑ and FIR splice variant: FIR del/exon2 | Absence of MYC repression | Resistance to apoptosis ↑, tumor growth ↑ | [56, 134] |
FUBP1 ↑ | NA | [166] | ||
Breast cancer | FUBP1 ↑ | MYC ↑ | Proliferation ↑, tumor growth ↑ | [34] |
Clear cell renal cancer | FUBP1 ↑ | MYC ↑ | [24] | |
MYC ↑, P21 ↑ | Proliferation ↑, apoptosis ↓ | [10] | ||
Bladder cancer | FUBP1 ↑ | NA (not MYC) | [24] | |
Ovarian cancer cells | FUBP1 ↑ | NA | [167] | |
NA | Resistance ↑ | [117, 118] | ||
Prostate cancer | FUBP1 ↑ | NA (not MYC) | [24] | |
Nasopharyngeal carcinoma | FUBP1 ↑ | MYC ↑ | Proliferation ↑, colony formation ↑ and resistance ↑ | [116] |
MYC | Resistance ↑ | [168] | ||
Esophageal squamous cell carcinoma | FUBP1 ↑ | MYC ↑ | Proliferation ↑, G1/S cell cycle transition ↑ | [14] |
Non-small cell lung cancer | FUBP1 ↑ | Stathmin 1/3 ↑ | Proliferation ↑, migration ↑ and matrix invasion ↑ | [12] |
FIR ↑ FUBP1 | [130] | |||
Sacral chordomas | FUBP1 ↑ | MYC ↑ | Proliferation ↑, invasion ↑ | [127] |
NA not available